To include your compound in the COVID-19 Resource Center, submit it here.

Advaxis raises $20M in follow-on

Cancer immunotherapy company Advaxis Inc. (NASDAQ:ADXS) raised $20 million on Feb. 22 through

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE